title: [Clinical study on treatment of advanced stage non-small cell lung cancer by guben xiaoliu capsule].
abstract: OBJECTIVE
  To observe the therapeutic effect of Guben Xiaoliu Capsule (GXC) in treating advanced stage non-small cell lung cancer (NSCLC).
  
  
  METHODS
  One hundred and ninety-eight NSCLC in-patients were divided into the integrative treated group [Group A, 54 patients treated with chemotherapy (CT) plus GXC], the TCM treated group (Group B, 96 patients treated with GXC alone) and the chemotherapeutic group (Group C, 48 patients treated with CT alone). Randomized controlled observation was applied to the Group A and C. The clinical effect, quality of life (QOL), adverse reaction and survival period in the three groups were observed.
  
  
  RESULTS
  The immediate effective rate (CR + PR) in the Group A, B and C was 16.7%, 3.1% and 8.3%, respectively, in the Group A, it was better than that in the other two groups (P < 0.05). The improvement of clinical symptoms and QOL in the Group A and B were superior to those in the Group C (P < 0.05). The median survival rate in the three groups was 12, 15 and 9 months, respectively, the 1-, 2- and 3-year survival rate in Group A being 57.4%, 11.1% and 3.7%, respectively, in Group B, 67.7%, 9.4% and 3.1%, and in (Group C, 39.6%, 4.2% and 0, respectively, comparison between the three groups showed that the survival rates in the former two were higher than those in Group C (P < 0.05). Moreover, the incidence rate and degree of CT toxicity were milder in Group A than those in Group C (P < 0.05).
  
  
  CONCLUSIONS
  GXC has definite effect in treating NSCLC, it could raise the QOL, prolong the survival period of patients, also reduce the toxicity and enhance the efficacy of CT.
authors.affiliation: Department of Oncology, Beijing Hospital of TCM, Beijing. ntxmloo@sina.com
authors.forename: Xiao-min
authors.initials: XM
authors.lastname: Wang
authors.forename: Hai
authors.initials: H
authors.lastname: Xin
authors.forename: Zhong
authors.initials: Z
authors.lastname: Yang
authors.forename: Wenshui
authors.initials: W
authors.lastname: Zhao
authors.forename: Guowang
authors.initials: G
authors.lastname: Yang
authors.forename: Ju
authors.initials: J
authors.lastname: Liu
authors.forename: Wujun
authors.initials: W
authors.lastname: Tang
authors.forename: Qing
authors.initials: Q
authors.lastname: Zhang
authors.forename: Dong
authors.initials: D
authors.lastname: Han
authors.forename: Rencun
authors.initials: R
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002214:Capsules; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage; D008517:Phytotherapy; D011788:Quality of Life; D016019:Survival Analysis; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D002214:Capsules; D004365:Drugs, Chinese Herbal; D008937:Mitomycins; D014747:Vinblastine; D002945:Cisplatin